Literature DB >> 10852915

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules.

H R Ashar1, L James, K Gray, D Carr, S Black, L Armstrong, W R Bishop, P Kirschmeier.   

Abstract

Human tumor cell lines that are sensitive to the effects of farnesyl transferase inhibitors accumulate in G(2) --> M (except for cells with an activated Ha-ras that accumulate in G(1)). A search for CAAX box proteins from Swiss-Prot revealed more than 300 peptides. Of these, the centromeric proteins CENP-E and CENP-F are preferentially expressed during mitosis and are implicated as mediators of the G(2) --> M checkpoint. Experiments performed here show that peptides from the COOH-terminal CAAX box of CENP-E and CENP-F are substrates for farnesyl transferase but not geranylgeranyl transferase-I. Although both proteins are prenylated in the human tumor cell line DLD-1, their prenylation is completely inhibited by the farnesyl transferase inhibitor, SCH 66336. Immunohistochemical data with the lung carcinoma cell line, A549, showed that preventing the farnesylation of CENP-E and CENP-F by treatment with the farnesyl transferase inhibitor SCH 66336 does not affect their localization to the kinetochores. However, the presence of farnesyl transferase inhibitors alters the association between CENP-E and the microtubules. Our results imply that the inhibition of CENP-E farnesylation results in the alteration of the microtubule-centromere interaction during mitosis and results in the accumulation of cells prior to metaphase.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10852915     DOI: 10.1074/jbc.M003469200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  78 in total

Review 1.  Evolving therapies: farnesyltransferase inhibitors.

Authors:  W Thomas Purcell; Ross C Donehower
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.075

Review 2.  Preclinical and clinical evaluation of farnesyltransferase inhibitors.

Authors:  Charles Baum; Paul Kirschmeier
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

3.  Enlarged meristems and delayed growth in plp mutants result from lack of CaaX prenyltransferases.

Authors:  Mark P Running; Meirav Lavy; Hasana Sternberg; Arnaud Galichet; Wilhelm Gruissem; Sarah Hake; Naomi Ori; Shaul Yalovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

4.  Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor.

Authors:  Sarah J O'Meara; B Therese Kinsella
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

Review 5.  Protein farnesylation and disease.

Authors:  Giuseppe Novelli; Maria Rosaria D'Apice
Journal:  J Inherit Metab Dis       Date:  2012-02-04       Impact factor: 4.982

6.  A novel function of Rab5 in mitosis.

Authors:  Letizia Lanzetti
Journal:  Small GTPases       Date:  2012-06-14

Review 7.  Regulatory mechanisms of kinetochore-microtubule interaction in mitosis.

Authors:  Kozo Tanaka
Journal:  Cell Mol Life Sci       Date:  2012-07-04       Impact factor: 9.261

8.  Genome-wide screen for modulation of hepatic apolipoprotein A-I (ApoA-I) secretion.

Authors:  Rebecca R Miles; William Perry; Joseph V Haas; Marian K Mosior; Mathias N'Cho; Jian W J Wang; Peng Yu; John Calley; Yong Yue; Quincy Carter; Bomie Han; Patricia Foxworthy; Mark C Kowala; Timothy P Ryan; Patricia J Solenberg; Laura F Michael
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

9.  Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.

Authors:  Helen Court; Marc Amoyel; Michael Hackman; Kyoung Eun Lee; Ruliang Xu; George Miller; Dafna Bar-Sagi; Erika A Bach; Martin O Bergö; Mark R Philips
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

Review 10.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.